Compare CNTN & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNTN | EARN |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.2M | 200.3M |
| IPO Year | 2022 | 2012 |
| Metric | CNTN | EARN |
|---|---|---|
| Price | $3.41 | $4.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 533.9K | ★ 570.3K |
| Earning Date | 02-23-2026 | 03-04-2026 |
| Dividend Yield | N/A | ★ 21.92% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.43 |
| Revenue Next Year | N/A | $24.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.46 | $4.31 |
| 52 Week High | $5.27 | $6.08 |
| Indicator | CNTN | EARN |
|---|---|---|
| Relative Strength Index (RSI) | 24.60 | 26.15 |
| Support Level | N/A | N/A |
| Resistance Level | $4.78 | $5.36 |
| Average True Range (ATR) | 0.34 | 0.14 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 10.63 | 13.38 |
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.